LINC 2017 programme

Find all topics and speakers listed below.

Room 1 - Main Arena 1

22 events
  • Tuesday, January 24th: - , Room 1 - Main Arena 1

    SYMPOSIUM: New evidence for broadened indications using new generation stents in fempop obstructions

    Moderator:
    Dierk Scheinert
    Panel:
    Andrej Schmidt, Marcus Treitl, Miguel Montero-Baker, Konstantinos Katsanos, Luis Mariano Palena, Yann Gouëffic
    1. -

      Overview of all available stents for use in the SFA/popliteal arteries

        Andrej Schmidt
    2. -

      Stent design matters – results from a single operator registry

        Marcus Treitl
    3. -

      Live case transmission from Leipzig

    4. -

      Advancing medical care in highly diseased patients – the US experience

        Miguel Montero-Baker
    5. -

      SUPERFAST – a prospective CTOs registry propensity matched with a historical SNS cohort

        Konstantinos Katsanos
    6. -

      The PRESTO technique for precise placement of the SUPERA in the SFA ostium and SUPERSUB update

        Luis Mariano Palena
    7. -

      CFA stenting experiences to date and insights into the CFA SUPERA study

        Yann Gouëffic
    8. -

      Live case transmission from Dendermonde

  • Tuesday, January 24th: - , Room 1 - Main Arena 1

    Drug-eluting devices for prevention of restenosis – the new standard for femoropopliteal interventions in claudicants

    Moderator:
    Dierk Scheinert, Ramon Varcoe
    Panel:
    John Laird, Marc Bosiers, Lawrence Garcia, Erich Minar
    1. -

      DCB CLINICAL TRIAL UPDATE

    2. -

      Update on 12-month results of the European and US Illumenate RCTs

        Sean Lyden
    3. -

      2-year results of the AcoArt1 – RCT for the use of the Orchid ® DCB in femoropopliteal artery disease

        Wei Guo
    4. -

      Current status of drug coated balloon treatment in the SFA: What do the 3 year outcomes from the IN.PACT SFA RCT tell us?

        John Laird
    5. -

      A real-world look at treatment effects of IN.PACT Admiral DCB: 12-month results from the IN.PACT Global Study full clinical cohort

        Marianne Brodmann
    6. -

      FIRST TIME DATA RELEASE: 6-month results of the RANGER RCT – diabetic subgroup

        Dierk Scheinert
    7. -

      FIRST TIME DATA RELEASE: 12-month results from the MDT-2113 SFA Japan trial – DCB vs. standard PTA for the treatment of atherosclerotic lesions in the SFA/PPA

        Osamu Iida
    8. -

      FIRST TIME DATA RELEASE: DCB: 12-month results of the CONSEQUENT RCT

        Thomas Albrecht
    9. -

      FIRST TIME DATA RELEASE: The Lutonix EU Long lesion study

        Dierk Scheinert
    10. -

      FIRST TIME DATA RELEASE: 12-month results of the Illumenate Global Study

        Thomas Zeller
    11. -

      FIRST TIME DATA RELEASE: Catheter-mediated deep adventitial microinfusion of dexamethasone for restenosis prevention in femoropopliteal arteries – 12-month results of the DANCE trial

        George Adams
    12. -

      FIRST TIME DATA RELEASE: 2-year results of the REAL-PTX randomised clinical trial comparing Zilver PTX vs. DCB treatment in femoropopliteal lesions

        Dierk Scheinert
    13. -

      2-year data from the MAJESTIC DES trial for treatment of femoropopliteal disease

        Stefan Müller-Hülsbeck
    14. -

      DCB + stent in the SFA: 12-month results of the Biolux4ever trial

        Marc Bosiers
    15. -

      Patterns of restenosis: a core lab driven assessment of SFA restenosis a potential shift to unify various trials

        Lawrence Garcia
    16. -

      Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease? The REALITY trial

        Giovanni Torsello
    17. -

      Are drug-eluting devices the new standard for femoropopliteal interventions in claudication?

        Peter Schneider
    18. -

      Discussion

  • Tuesday, January 24th: - , Room 1 - Main Arena 1

    SYMPOSIUM: Drug elution in the SFA: Leave the right thing behind. Debating evidence to provide an answer

    Moderator:
    Michael Dake
    Panel:
    Erwin Blessing, Aloke Finn, Iris Baumgartner
    1. -

      Introduction

    2. -

      Why and how to prep the vessel

        Erwin Blessing
    3. -

      Live case transmission from Dendermonde

    4. -

      Understanding restenosis in the SFA

        Aloke Finn
    5. -

      The importance of scientific evidence

        Iris Baumgartner
    6. -

      Live case transmission from Münster

    7. -

      Summing up on symposium

        Michael Dake
    8. -

      Discussion and debate

  • Tuesday, January 24th: - , Room 1 - Main Arena 1

    Lunch

  • Tuesday, January 24th: - , Room 1 - Main Arena 1

    SYMPOSIUM: Past, present, future: How DCB is enabling treatment of more complex femoropopliteal artery lesions

    Moderator:
    Dierk Scheinert, Krishna Rocha-Singh
    Panel:
    Thomas Zeller, John Laird, Osamu Iida, Juan Fernando Granada Solis
    1. -

      Introduction

        Dierk Scheinert
    2. -

      Evolution of DCB technology

        Juan Fernando Granada Solis
    3. -

      Discussion

    4. -

      Live case transmission from Leipzig

    5. -

      IN.PACT drug-coated balloon: Consistent clinical outcomes across patient populations

        John Laird
    6. -

      Discussion

    7. -

      Gain lumen, maintain patency: The power of adjunctive therapy with directional atherectomy and DCB

        Thomas Zeller
    8. -

      Discussion

    9. -

      Live case transmission from New York

    10. -

      Conclusion and summary

        Krishna Rocha-Singh
  • Tuesday, January 24th: - , Room 1 - Main Arena 1

    SYMPOSIUM: Redefining SFA treatment in a drug-eluting world

    Moderator:
    Dierk Scheinert, Iris Baumgartner
    Panel:
    Gunnar Tepe, Thomas Zeller, Konstantinos Katsanos
    1. -

      Introduction and learning objectives

        Iris Baumgartner
    2. -

      Drug coated balloons – for all or some?

        Gunnar Tepe
    3. -

      Eluvia drug eluting stent: A platform for success?

        Giovanni Torsello
    4. -

      Live case transmission from Leipzig

    5. -

      Getting to answers with clinical trials: being bold

        Thomas Zeller
    6. -

      Why you should care about health economics in PAD: Funding meaningful innovation

        Konstantinos Katsanos
    7. -

      Close and take home learnings

        Dierk Scheinert
  • Tuesday, January 24th: - , Room 1 - Main Arena 1

    THE LAST FRONTIERS: New concepts for calcified lesions

    Moderator:
    Chris Metzger, Hiroyoshi Yokoi
    Panel:
    Marcus Thieme, Gunnar Tepe, Lieven Maene, Thomas Heller, James McKinsey
    1. -

      Patterns of calcification: intimal vs. medial and differences below and above the knee

        Aloke Finn
    2. -

      The Shockwave lithoplasty concept – latest results

        Thomas Zeller
    3. -

      Live case transmission from Leipzig

    4. -

      Importance of thorough vessel preparation followed by anti-restenotic therapy: an update from the DEFINITIVE AR study

        Gunnar Tepe
    5. -

      Treatment of challenging calcified lesions with the next generation. Phoenix atherectomy system

        Michael Lichtenberg
    6. -

      Recorded case

        Michael Lichtenberg
    7. -

      10 steps to percutaneous bypass of extra long, complex SFA occlusions

        Grzegorz Halena
    8. -

      FIRST TIME DATA RELEASE: The DETOUR trial: Six-month outcomes of percutaneous bypass in long segment femoral-popliteal occlusions

        Dierk Scheinert
    9. -

      Live case transmission from New York

    10. -

      Discussion

  • Wednesday, January 25th: - , Room 1 - Main Arena 1

    Optimising outcome of BTK interventions in CLI – Current approaches and future outlook

    Moderator:
    Dierk Scheinert, Jihad Mustapha
    Panel:
    Peter Schneider, Ramon Varcoe, Juan Fernando Granada Solis, Osamu Iida, Frank Vermassen, Mohammad AlTwalah
    1. -

      Live case transmission from Leipzig – part I

    2. -

      Prognostic impact of revascularisation in poor-risk patients with critical limb ischaemia: The PRIORITY registry

        Osamu Iida
    3. -

      What have we learned from past DCB BTK studies: Technology, clinical study design, and patient management

        Thomas Zeller
    4. -

      Does paclitaxel interfere with wound healing?

        Juan Fernando Granada Solis
    5. -

      How do I treat BTK/CLI with DCB: Past experience and a new beginning

        Francesco Liistro
    6. -

      Drug eluting devices: Why paclitaxel works above the knee and sirolimus below the knee, is the stent or the drug?

        Aloke Finn
    7. -

      The clinical rationale: Why endpoints for CLI trials should be evaluated at 6 months instead of 1 year

        Jihad Mustapha
    8. -

      Alternative methods of drug delivery: The LIMBO trial

        George Adams
    9. -

      Live case transmission from Leipzig – part II

    10. -

      Towards optimised BTK results by preventing recoil and sealing dissections – TOBA BTK

        Marianne Brodmann
    11. -

      Bioabsorbable scaffolds in BTK arteries: 24-month results from ABSORB BTK

        Ramon Varcoe
    12. -

      1-year results in real world patients with ABSORB BTK

        Steven Kum
    13. -

      Dealing with calcification in BTK arteries – is lithoplasty the answer?

        Andrew Holden
    14. -

      Percutanoues deep venous arteriolisation for no-option CLI – 1-year results

        Steven Kum
  • Wednesday, January 25th: - , Room 1 - Main Arena 1

    SYMPOSIUM: Leading DCB era in China – Current evidence and practice

    Moderator:
    Wei Guo
    Panel:
    Dierk Scheinert, Weiguo Fu, Zhong Chen, Zhidong Ye, Francesco Liistro
    1. -

      DCB is changing the treatment paradigm of femoral-popliteal lesions in China

        Wei Guo
    2. -

      Orchid DCB in Leipzig – real world experience

        Dierk Scheinert
    3. -

      Orchid DCB brings new life to a ISR patient – Story behind 31 month patency

        Baixi Zhuang
    4. -

      How did DCB change my treatment principle in femoral-popliteal lesions

        Bao Liu
    5. -

      Long DCB in long lesion – benefits for lesions beyond 150mm

        Weiwei Wu
    6. -

      Atherectomy plus DCB: China experience

        Lian Rui Guo
    7. -

      DCB in BTK: Preliminary result from Acoart BTK study

        Francesco Liistro
    8. -

      Live case transmission from Leipzig

    9. -

      Discussion and summary

  • Wednesday, January 25th: - , Room 1 - Main Arena 1

    SYMPOSIUM: Proven long-term outcomes for complex femoropopliteal lesions

    Moderator:
    Giovanni Torsello
    Panel:
    Peter Soukas, Takao Ohki, Michel Reijnen, Jorge Fernández Noya
    1. -

      The endoluminal bypass – What have we learnt so far

        Peter Soukas
    2. -

      Live case transmission from Münster

    3. -

      How to achieve good results with Gore Viabahn for treating complex femoropopliteal occlusive disease: Results from the Japanese IDE trial

        Takao Ohki
    4. -

      Discussion

    5. -

      Live case transmission from Leipzig

    6. -

      Dealing with edge stenosis and outcomes of failed endografts

        Michel Reijnen
    7. -

      Discussion

    8. -

      Best practices in the treatment of TASC C & D lesion of femoro-popliteal district in CLI patient 4-year results

        Jorge Fernández Noya
    9. -

      Discussion and conclusion

  • Wednesday, January 25th: - , Room 1 - Main Arena 1

    Lunch

  • Wednesday, January 25th: - , Room 1 - Main Arena 1

    SYMPOSIUM: Lutonix® Drug Coated Balloon – Evidence in SFA, BTK, and AV

    Moderator:
    Dierk Scheinert
    Panel:
    Aloke Finn, Michael Lichtenberg, Antonio Micari, Scott O. Trerotola
    1. -

      Introduction

        Dierk Scheinert
    2. -

      A study of downstream events of the two leading DCBs on the market

        Aloke Finn
    3. -

      Lutonix® efficacy in BTK: Results of Lutonix® drug-coated balloons angioplasty in below the knee arteries in critical limb ischemia patients

        Antonio Micari
    4. -

      Clinical benefits at 12-month from the Lutonix EU long lesion study

        Dierk Scheinert
    5. -

      Live case transmission from Leipzig

    6. -

      An interim look at the Lutonix®DCB Global Real World BTK registry - 6-month outcomes

        Michael Lichtenberg
    7. -

      A first look at the LUTONIX® Catheter IDE clinical trial demographics, lesion, and procedural variables in AV fistula

        Scott O. Trerotola
    8. -

      Lutonix® efficacy in AV: On-going PAVE study

        Konstantinos Katsanos
    9. -

      Conclusion and FAQ

        Dierk Scheinert
  • Wednesday, January 25th: - , Room 1 - Main Arena 1

    VIVA@LINC: DCBs – Where we are and where do we need to be?

    Moderator:
    Michael Dake
    Panel:
    Krishna Rocha-Singh, Lawrence Garcia, Saher Sabri, Peter Schneider
    1. -

      Announcement of the winners of the Vascular Career Award 2016

        Antonio Micari, Saher Sabri
    2. -

      DCB Potential beyond the selected SFA lesion types studied in trials to date: What we know about the real world

        Krishna Rocha-Singh
    3. -

      Live case transmission from Columbus

    4. -

      Current views on vessel prep prior to DCB – pre-dil, atherectomy, etc., what we’ve learned

        Lawrence Garcia
    5. -

      Current status of DCB experience with non-femoropopliteal applications (dialysis, tibial, venous, etc.)

        Saher Sabri
    6. -

      Live case transmission from Columbus

    7. -

      DCB and restenosis; who fails and why: What we do about it now and what the future holds

        Peter Schneider
  • Wednesday, January 25th: - , Room 1 - Main Arena 1

    New concepts for complex femoropopliteal disease

    Moderator:
    Marc Bosiers, Takao Ohki
    Panel:
    Sabine Steiner, Dong-Hoon Choi, Ralf Langhoff, Antonio Micari, James McKinsey, Osamu Iida
    1. -

      2-year outcomes from the DEB-SFA-Long Study

        Antonio Micari
    2. -

      Tack-optimised angioplasty (TOBA) – Update on latest data and current projects

        George Adams
    3. -

      6-month results of the LOCOMOTIVE registry investigating spot stenting in the femoropopliteal tract

        Klaus Amendt
    4. -

      The MIMICS-2 IDE study: interim update on BioMimics 3D in US, Japan, and Europe

        Thomas Zeller
    5. -

      Live case transmission from Leipzig

    6. -

      FIRST TIME DATA RELEASE: 2-year results of the VIABAHN Japan IDE trial for complex SFA lesions

        Takao Ohki
    7. -

      FIRST TIME DATA RELEASE: 3-year results of ZEPHYR (ZilvEr PTX for tHe Femoral ArterY and Proximal Popliteal ArteRy) study

        Osamu Iida
    8. -

      Live case transmission from Columbus

    9. -

      Comparing endoluminal bypass to open fempop bypasses: Final 1-year results of the SUPERB trial

        Michel Reijnen
    10. -

      Surgical bypass vs. ZilverPTX stent for long SFA lesions: Interim results of the Zilverpass trial

        Koen Deloose
  • Thursday, January 26th: - , Room 1 - Main Arena 1

    THE LAST FRONTIERS: Complex tibial and below-the-ankle interventions

    Moderator:
    Jihad Mustapha, Roberto Ferraresi
    Panel:
    Frank Vermassen, Michael Edmonds, Keisuke Hirano, Steven Kum, Sigrid Nikol
    1. -

      Live case transmission from Leipzig

    2. -

      Angiosome revascularisation strategies in real world practice: how much difference does it make?

        Peter Schneider
    3. -

      Retrograde tibial puncture has changed the algorithm for crossing tibial lesions in CLI: How and when to do It?

        Jihad Mustapha
    4. -

      A systematic review of results with the retrograde tibial approach

        Olaf Bakker
    5. -

      Live case transmission from Abano Terme

    6. -

      When is below-the-ankle angioplasty indicated and how to introduce it into your practice

        Roberto Ferraresi
    7. -

      Aggressive below-the-ankle intervention: Its effect on long term outcome

        Kazushi Urasawa
    8. -

      Discussion and conclusion

  • Thursday, January 26th: - , Room 1 - Main Arena 1

    SYMPOSIUM: Built on evidence: Stellarex DCB technology and clinical program

    Moderator:
    Sean Lyden
    Panel:
    Marianne Brodmann, Stephan Duda, Henrik Schröder, Giovanni Torsello, Michael Lichtenberg
    1. -

      4 trials/1.000+ patients: results from the ILLUMENATE SFA program

        Marianne Brodmann
    2. -

      Live case transmission from Bad Krozingen

    3. -

      Stellarex evidence in diabetics

        Stephan Duda
    4. -

      Stellarex evidence in females

        Henrik Schröder
    5. -

      Role of vessel preparation in contemporary DCB practice

        Michael Lichtenberg
    6. -

      Live case transmission from Leipzig

    7. -

      Discussion and conclusion

  • Thursday, January 26th: - , Room 1 - Main Arena 1

    Glimpse into the future: New treatment approaches and technologies for peripheral arterial disease

    Moderator:
    William Gray, Marianne Brodmann
    Panel:
    Andrew Holden, George Adams, Bob Smouse, Stephan Duda, Andrej Erglis
    1. -

      Clinical outcomes and magnetic resonance angiography assessment of a new dual component vascular stent

        Konstantinos Katsanos
    2. -

      Design principles of the BioMimics 3D stent and why it's ideal for fempop intervention

        Bob Smouse
    3. -

      Real world experience with BioMimics 3D, the swirling flow stent

        Michael Lichtenberg
    4. -

      Live case transmission from Bad Krozingen

    5. -

      FIRST TIME DATA RELEASE: Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of femoropopliteal lesions

        Andrew Holden
    6. -

      Direct micropuncture mediated deep adventitial drug delivery – New insights from the DANCE project and future prospects

        Dierk Scheinert
    7. -

      Percutaneous bypass with the DETOUR procedure: Using the femoral vein as a natural conduit ... In situ with a twist!

        Grzegorz Halena
    8. -

      Live case transmission from Münster

    9. -

      New evidence review for OCT guided atherectomy: Long term patency, in-stent restenosis, and zero contrast/fluoroscopy in CKD patients

        Jihad Mustapha
    10. -

      Future of OCT guided technologies for PAD: True lumen measurement, BTK platform, and calcium therapies

        Jon George
  • Thursday, January 26th: - , Room 1 - Main Arena 1

    LUNCH SYMPOSIUM: Live case with Dr. Andrej Schmidt: Sophisticated CLI access and crossing techniques

    Moderator:
    Craig Walker
    Panel:
    Roberto Ferraresi, Flavio Airoldi, Miguel Montero-Baker
    live with:
    Andrej Schmidt
  • Thursday, January 26th: - , Room 1 - Main Arena 1

    Treatment of complex aortoiliac disease: Latest techniques and results

    Moderator:
    Hans Krankenberg, Patrick Peeters
    Panel:
    Peter Goverde, Frank Vermassen, Gustavo Oderich, Peter Soukas, Patrice Mwipatayi
    1. -

      Live case transmission from Leipzig

    2. -

      Outcomes of polytetrafluoroethylene-covered stent in the primary treatment of severe iliac artery obstructive lesions

        Michelangelo Ferri
    3. -

      Endovascular treatment of severe TASC C and D external iliac artery occlusive disease

        Bertrand Saint-Lèbes
    4. -

      Final results of the BOLSTER study: A prospective, multicenter study of a balloon-expandable ePTFE-covered stent for obstructive lesions in the iliac artery

        Andrew Holden
    5. -

      Covered endovascular reconstruction of the aortic bifurcation (CERAB) as treatment of extensive aortoiliac occlusive disease: 3-year results

        Peter Goverde
    6. -

      Live case transmission from Bad Krozingen

    7. -

      Discussion

  • Thursday, January 26th: - , Room 1 - Main Arena 1

    Challenges and new concepts in hemodialysis access and upper extremity interventions

    Moderator:
    Andrew Holden, Stephan Duda
    Panel:
    Konstantinos Katsanos, Daniela Branzan, Roberto Ferraresi
    1. -

      Strategy and technical tips in treating AV fistulas

        Jos van den Berg
    2. -

      Review of clinical evidence: The role of DCB for the treatment of failing dialysis access stenosis

        Konstantinos Katsanos
    3. -

      FIRST TIME DATA RELEASE: 6-month results of the Lutonix US IDE trial for treatment of AV-fistula obstructions in HD patients

        Scott O. Trerotola
    4. -

      Technical aspects for treating AV fistulae with IN.PACT DCB

        Andrew Holden
    5. -

      Endovascular treatment for central venous obstruction in hemodialysis patients

        Wei Liang
    6. -

      Live case transmission from Münster

    7. -

      Shifting the paradigm for dialysis access: The latest everlinQ endoAVF clinical experience and technology evolution – T. Steinke

    8. -

      What is the true cause of critical hand ischaemia? Results in a large cohort of hemodialysis patients

        Roberto Ferraresi
    9. -

      Thrombolytic therapy of distal upper extremity occlusions (hypothenar hammer syndrome): A therapeutic option for a rare disease

        Marianne Brodmann
    10. -

      Discussion

  • Thursday, January 26th: - , Room 1 - Main Arena 1

    THE LAST FRONTIERS: Interventional treatment of common femoral and popliteal artery disease

    Moderator:
    Lawrence Garcia, Marc Bosiers
    Panel:
    Bob Smouse, Sven Seifert, Torsten Fuß, Yann Gouëffic, Chris Metzger, Wei Liang
    1. -

      The common femoral artery – an anatomical region still reserved for treatment by the surgeons?

        Marianne Brodmann
    2. -

      Stenting of the common femoral artery for atherosclerotic lesions: is it feasible and how and when we do it

        Peter Goverde
    3. -

      Live case transmission from Bad Krozingen

    4. -

      A randomized comparison of endovascular versus surgery treatment of common femoral artery disease: Results from the TECCO trial

        Yann Gouëffic
    5. -

      First experiences in the VMI-CFA study: investigating the Supera stent in the common femoral artery. Is the Supera a valuable alternative for common femoral endarterectomy?

        Koen Deloose
    6. -

      Live case transmission from Leipzig

    7. -

      DCB for popliteal artery stenosis: The IN.PACT Flexion trial

        Patrick Peeters
    8. -

      Directional atherectomy plus DCB versus DCB alone for isolated lesions of the popliteal artery

        Konstantinos Stavroulakis
  • Friday, January 27th: - , Room 1 - Main Arena 1

    Critical issues and pioneering solutions in aortic endografting

    Moderator:
    Martin Malina, Marc van Sambeek
    Panel:
    Eric Verhoeven, Thomas Larzon, Piotr Kasprzak, Karin Brachmann
    1. -

      Live case transmission from Münster

    2. -

      Endovascular and hybrid approach in the treatment of aberrant subclavian artery and its aneurysm

        Thomas Larzon
    3. -

      In patients with a ruptured it is justified to push the borders of anatomical suitability

        Marc van Sambeek
    4. -

      Infected stentgrafts and aneurysms of the aorta: Endovascular repair offers lower early mortality and similar long term results as open repair

        Martin Malina
    5. -

      Infective complications after TEVAR: Incidence and treatment options

        Andrea Kahlberg
    6. -

      Live case transmission from Leipzig

    7. -

      Association between polycystic kidney disease and aortic aneurysm, presentation of case report and literature review

        Erik Debing
    8. -

      Impact of iliac arteries anatomy on the outcome of FB – EVAR

        Mauro Gargiulo
    9. -

      Retroperitioneal access to target arteries: a bail-out procedure when prograde branch catheterisation does not work for F/B EVAR

        Eric Verhoeven
    10. -

      Live case transmission from Münster

    11. -

      Discussion and conclusion